A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer

NCT01647828 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

217

Enrollment

INDUSTRY

Sponsor class

Conditions

Stage IV Pancreatic Cancer

Interventions

DRUG: OMP-59R5
DRUG: Gemcitabine
DRUG: Placebo
DRUG: Nab-Paclitaxel

Sponsor

OncoMed Pharmaceuticals, Inc.